UK markets close in 8 hours 7 minutes

Valneva SE (VALN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
19.76-0.20 (-1.00%)
At close: 03:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close19.96
Open19.35
Bid0.00 x 1800
Ask0.00 x 800
Day's range19.35 - 20.16
52-week range13.71 - 67.84
Volume6,178
Avg. volume25,566
Market cap1.158B
Beta (5Y monthly)0.93
PE ratio (TTM)N/A
EPS (TTM)-1.49
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est39.68
  • Globe Newswire

    VALNEVA - Declaration of shares and voting rights - July 31, 2022

    VALNEVA Declaration of shares and voting rights July 31, 2022__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment A Declaration date: August 4, 2022 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the changeDate on which this change was

  • Globe Newswire

    Valneva Confirms Amendment of Advance Purchase Agreement with European Commission for Valneva’s Inactivated COVID-19 Vaccine

    Saint-Herblain (France), August 1, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today confirms the signing of the amendment to its Advance Purchase Agreement (APA)1 with the European Commission (EC), following expiration of the Member States’ opt-out period, as announced by the Company on July 20, 20222. Under this amendment, the Member States’ purchases of VLA2001, Valneva’s inactivated whole-virus COVID-19 vaccine, consist of 1.25 million doses of VLA2001

  • Globe Newswire

    European Commission Approves Purchase Agreement Amendment for Valneva’s Inactivated COVID-19 Vaccine

    European Commission to order 1.25 million doses of Valneva’s whole-virus COVID-19 vaccine VLA2001 in 2022 Saint-Herblain (France), July 20, 2022 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces that the European Commission (EC) has approved an amendment to the Advance Purchase Agreement (APA) it signed in November 20211 for Valneva’s inactivated whole-virus COVID-19 vaccine, VLA2001. The amendment will be signed after a mandatory five-day period duri